ArticleRevista peruana de medicina experimental y salud publica2025
Development and evaluation of loop-mediated isothermal amplification (lamp) for rapid detection of campylobacter jejuni.
Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVES.: To develop and evaluate a loop-mediated isothermal amplification (LAMP) assay for the rapid detection of Campylobacter jejuni in stool samples associated with acute diarrheal disease (ADD) and Guillain-Barré syndrome (GBS) for implementation in regional laboratories and primary health care centers. MATERIALS AND METHODS.: Four sets of LAMP primers for C. jejuni were designed and initially evaluated with DNA from C. jejuni, Campylobacter coli, Salmonella Infantis, and Escherichia coli extracted using a commercial kit. The best-performing primer set was selected for assay optimization, determination of the limit of detection, and analytical validation with DNA from the aforementioned strains. Subsequently, clinical validation was performed using stool samples from patients with suspected ADD due to C. jejuni, applying the same standardized conditions used for the strain DNA samples. The sensitivity and specificity of the test were determined using real-time PCR (qPCR) as the standard. RESULTS.: The LAMP assay for the detection of C. jejuni in stool samples using a primer set for the cdtC region showed a sensitivity of 97% (CI: 81.49-99.83%), a specificity of 93% (CI: 75.79-98.80%), a positive predictive value of 94% (CI: 77.78-98.91%), and a negative predictive value of 96% (CI: 79.76-99.81%). Furthermore, a strong agreement was demonstrated between this LAMP assay and qPCR (k=0.9). CONCLUSIONS.: The LAMP assay based on the cdtC gene is a reliable and rapid method, with high sensitivity and specificity comparable to qPCR for the identification of C. jejuni associated with ADD and GBS, especially in low-resource areas, due to its low cost and ease of implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.